Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFEQ6S)

• Drug Name: 3,5-DHPG Drug Info
• Synonyms: 3,5-dihydroxyphenylglycine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 108001
  ChEBI ID: CHEBI:93822
  CAS Number: CAS 146255-66-5
  TTD Drug ID: DMFEQ6S

Molecule-Related Drug Atlas

Drug(s) Targeting Metabotropic glutamate receptor 1 (mGluR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-1913539	DMXEU14	Alzheimer disease	8A20	Discontinued in Phase 3	[4]
AZD8529	DMEQ2N1	Schizophrenia	6A20	Discontinued in Phase 2	[5]
AZD-9272	DMYSBN3	Neuropathic pain	8E43.0	Discontinued in Phase 1	[6]
NPS-2390	DMMRY0Z	Cerebrovascular ischaemia	8B1Z	Preclinical	[7]
A-841720	DMSO8IE	Pain	MG30-MG3Z	Preclinical	[8]
LY-367385	DM98POQ	Neurological disorder	6B60	Terminated	[9]
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[10]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[3]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[3]
(+)-MCPG	DMG5QJB	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[11]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[12]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[13]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[14]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[15]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[16]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[17]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[18]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[19]
BMS-984923	DMFNDUL	Alzheimer disease	8A20	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 1 (mGluR1)	TTVBPDM	GRM1_HUMAN	Agonist	[2]
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Agonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1367).
• [2] [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
• [3] Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
• [4] Pfizer. Product Development Pipeline. March 31 2009.
• [5] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [6] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [7] Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
• [8] Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition. Behav Pharmacol. 2007 Jul;18(4):273-81.
• [9] Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24.
• [10] Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7.
• [11] Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
• [12] Pipeline of Addex Pharma. Addex Pharma. 2009.
• [13] The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
• [14] Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
• [15] A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
• [16] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
• [18] Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
• [19] Clinical pipeline report, company report or official report of Roche.
• [20] Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.